Phase I study of adjuvant immunotherapy with autologous tumor-infiltrating lymphocytes in locally advanced cervical cancer,The Journal of Clinical Investigation

当前位置： X-MOL 学术 › J. Clin. Invest. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Phase I study of adjuvant immunotherapy with autologous tumor-infiltrating lymphocytes in locally advanced cervical cancer
The Journal of Clinical Investigation ( IF 13.3 ) Pub Date : 2022 , DOI: 10.1172/jci157726
He Huang _{1,

2} , Cai-Ping Nie _{1,

3} , Xiu-Feng Liu _{1,

3} , Bin Song _{4,

5} , Jian-Hui Yue _{4,

6} , Jing-Xiao Xu _{1,

3} , Jia He _{1,

3} , Kui Li _{1,

3} , Yan-Ling Feng _{1,

2} , Ting Wan _{1,

2} , Min Zheng _{1,

2} , Yan-Na Zhang _{1,

2} , Wei-Jun Ye _{1,

7} , Jun-Dong Li _{1,

2} , Yan-Fang Li _{1,

2} , Jun-Yun Li _{1,

7} , Xin-Ping Cao _{1,

7} , Zhi-Min Liu _{1,

2} , Xiao-Shi Zhang _{1,

3} , Qing Liu _{1,

8} , Xi Zhang ₄ , Ji-Hong Liu _{1,

2} , Jiang Li _{1,

3}

Affiliation

BACKGROUND. Adoptive cell therapy (ACT) with tumor-infiltrating lymphocytes (TILs) has achieved remarkable clinical efficacy in metastatic cancers such as melanoma and cervical cancer (CC). Here, we explored the safety, feasibility, and preliminary tumor response and performed translational investigations of adjuvant immunotherapy using infusion of autogenous TILs (auto-TILs) following concurrent chemoradiotherapy (CCRT) in patients with CC who had locally advanced disease.

中文翻译：

自体肿瘤浸润淋巴细胞辅助免疫治疗局部晚期宫颈癌的Ⅰ期研究

背景。肿瘤浸润淋巴细胞 (TIL) 的过继细胞疗法 (ACT) 在黑色素瘤和宫颈癌 (CC) 等转移性癌症中取得了显着的临床疗效。在这里，我们探讨了在局部晚期疾病 CC 患者同步放化疗 (CCRT) 后使用输注自体 TIL (auto-TIL) 的辅助免疫治疗的安全性、可行性和初步肿瘤反应的转化研究。

更新日期：2022-08-02

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文